Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping By Ogkologos - November 11, 2024 796 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SCRUM-Japan GOZILA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Cure Probability Models for Evaluation of Patients with a Previous Cancer... October 26, 2021 Researchers Discover New Way to Prevent Hair Loss During Chemotherapy Treatment September 12, 2019 Καρκίνος οισοφάγου January 22, 2019 Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer January 11, 2021 Load more HOT NEWS Opinion: ‘Wales needs more than a three-page statement to get cancer... News digest – Genetic links to male breast cancer, bowel cancer... Marking Breast Cancer Awareness Month 2025, ESMO Calls for Increasing Awareness... ESMO Recommendations on Cancer Care Reflected in Un ECOSOC Ministerial Declaration...
